Amgen has completed the transaction announced in November 2019 for the strategic collaboration with BeiGene that aims to significantly accelerate and expand Amgen’s oncology presence in China. BeiGene is a research-based, oncology-focused biotechnology company with an established team in China, including 700 in the commercial organization and a 600 in the clinical development organization. As part of the collaboration Amgen will acquire a 20.5% stake in BeiGene for approximately $2.7 billi...